Literature DB >> 18086845

Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days.

Jeremy P Nuttall1, Daryl C Thake, Mark G Lewis, John W Ferkany, Joseph W Romano, Mark A Mitchnick.   

Abstract

Dapivirine is a nonnucleoside reverse transcriptase inhibitor being developed as a topical microbicide for the prevention of human immunodeficiency virus infection. The distribution of radioactivity and drug in plasma and in vaginal, cervical, and draining lymph node tissues was investigated after daily application of a vaginal gel formulation of [14C]dapivirine to rhesus macaques. This was preceded by a preliminary study with rabbits. Following the intravaginal administration of [14C]dapivirine ( approximately 0.1 mg/ml [15 microCi/ml]) to rabbits (0.5 ml/day) and macaques (1 ml/day) for 7 days, the dapivirine levels associated with vaginal and cervical tissue samples 1 h after the final dose were high (quantities of microg/g of tissue) and remained detectable at 24 h (mean, >or=2.5 ng/g in rabbits) and 48 h (mean, >80 ng/g in macaques). Radioactivity levels were low in the plasma and very low or unquantifiable in the draining lymph nodes of the macaques. Microautoradiography identified drug-related material (DRM) on the surfaces of the vaginal and cervical tissues of the rabbits and macaques. Although DRM was primarily associated with the outermost layer of shedding cells in rabbits, two animals showed some evidence of small quantities in the mucosal epithelium of the cervix. In macaques, DRM was seen within the keratinized layer of the vaginal epithelium and and was found to extend into the superficial cellular layers, and in at least one animal it appeared to be present in the deepest (germinal) layer of the epithelium and in submucosal tissues. The persistence of biologically significant concentrations of dapivirine in vaginal and cervical tissues for >24 h supports the development of dapivirine as a microbicide for once daily application.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086845      PMCID: PMC2258487          DOI: 10.1128/AAC.00330-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.

Authors:  Osmond J D'Cruz; Fatih M Uckun
Journal:  J Antimicrob Chemother       Date:  2006-01-23       Impact factor: 5.790

2.  Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.

Authors:  G Borkow; J Barnard; T M Nguyen; A Belmonte; M A Wainberg; M A Parniak
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

3.  Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.

Authors:  Vicky A Jespers; Jens M Van Roey; Greet I Beets; Anne M Buvé
Journal:  J Acquir Immune Defic Syndr       Date:  2007-02-01       Impact factor: 3.731

Review 4.  HIV and sexually transmitted diseases: lethal synergy.

Authors:  Myron S Cohen
Journal:  Top HIV Med       Date:  2004 Oct-Nov

5.  The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells.

Authors:  Patricia Fletcher; Yana Kiselyeva; Greg Wallace; Joseph Romano; George Griffin; Leonid Margolis; Robin Shattock
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

Authors:  Kalyan Das; Arthur D Clark; Paul J Lewi; Jan Heeres; Marc R De Jonge; Lucien M H Koymans; H Maarten Vinkers; Frederik Daeyaert; Donald W Ludovici; Michael J Kukla; Bart De Corte; Robert W Kavash; Chih Y Ho; Hong Ye; Mark A Lichtenstein; Koen Andries; Rudi Pauwels; Marie-Pierre De Béthune; Paul L Boyer; Patrick Clark; Stephen H Hughes; Paul A J Janssen; Eddy Arnold
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

Review 7.  Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors.

Authors:  Christine M Tarby
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

8.  Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation.

Authors:  Simonetta Di Fabio; Jens Van Roey; Giacomo Giannini; Guy van den Mooter; Massimo Spada; Andrea Binelli; Maria F Pirillo; Elena Germinario; Filippo Belardelli; Marie-Pierre de Bethune; Stefano Vella
Journal:  AIDS       Date:  2003-07-25       Impact factor: 4.177

9.  Disruption of the upper female reproductive tract epithelium by nonoxynol-9.

Authors:  Molina B Dayal; James Wheeler; Carmen J Williams; Kurt T Barnhart
Journal:  Contraception       Date:  2003-10       Impact factor: 3.375

10.  In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.

Authors:  Yven Van Herrewege; Jo Michiels; Jens Van Roey; Katrien Fransen; Luc Kestens; Jan Balzarini; Paul Lewi; Guido Vanham; Paul Janssen
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

  10 in total
  22 in total

Review 1.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Authors:  Fraser F Fleming; Lihua Yao; P C Ravikumar; Lee Funk; Brian C Shook
Journal:  J Med Chem       Date:  2010-08-30       Impact factor: 7.446

Review 2.  Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.

Authors:  Jessica L Adams; Angela D M Kashuba
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2012-02-04       Impact factor: 5.237

Review 3.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

4.  Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Authors:  Philippe Selhorst; Ana C Vazquez; Katty Terrazas-Aranda; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Jan Weber; Miguel E Quiñones-Mateu; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

5.  The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.

Authors:  Jonathon D S Holt; David Cameron; Nicola Dias; Jeremy Holding; Alex Muntendam; Freddy Oostebring; Peter Dreier; Lisa Rohan; Jeremy Nuttall
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

6.  Preclinical evaluation of UC781 microbicide vaginal drug delivery.

Authors:  Meredith R Clark; Timothy J McCormick; Gustavo F Doncel; David R Friend
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

7.  The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection.

Authors:  Meropi Aravantinou; Rachel Singer; Nina Derby; Giulia Calenda; Paul Mawson; Ciby J Abraham; Radhika Menon; Samantha Seidor; Daniel Goldman; Jessica Kenney; Guillermo Villegas; Agegnehu Gettie; James Blanchard; Jeffrey D Lifson; Michael Piatak; José A Fernández-Romero; Thomas M Zydowsky; Natalia Teleshova; Melissa Robbiani
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-27       Impact factor: 2.205

8.  Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice.

Authors:  José das Neves; Francisca Araújo; Fernanda Andrade; Mansoor Amiji; Maria Fernanda Bahia; Bruno Sarmento
Journal:  Pharm Res       Date:  2014-01-22       Impact factor: 4.200

9.  Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission.

Authors:  Ayman Akil; Michael A Parniak; Charlene S Dezzuitti; Bernard J Moncla; Marilyn R Cost; Mingguang Li; Lisa Cencia Rohan
Journal:  Drug Deliv Transl Res       Date:  2011-06-01       Impact factor: 4.617

10.  Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.

Authors:  Anna K Blakney; Yonghou Jiang; Dale Whittington; Kim A Woodrow
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-05-02       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.